CalciMedica’s (CALC) “Buy” Rating Reaffirmed at HC Wainwright

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $16.00 target price on the stock.

CalciMedica Trading Down 0.9 %

Shares of CalciMedica stock opened at $2.20 on Tuesday. The firm has a market capitalization of $29.66 million, a PE ratio of -2.04 and a beta of 1.18. CalciMedica has a 12 month low of $1.91 and a 12 month high of $6.27. The business’s 50-day moving average price is $2.78 and its 200-day moving average price is $3.46.

Institutional Investors Weigh In On CalciMedica

Several institutional investors have recently bought and sold shares of the stock. Atria Investments Inc increased its stake in shares of CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after buying an additional 15,296 shares during the period. Geode Capital Management LLC lifted its stake in shares of CalciMedica by 51.2% in the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock valued at $295,000 after purchasing an additional 22,525 shares during the period. PVG Asset Management Corp purchased a new position in CalciMedica during the third quarter valued at $67,000. Corient Private Wealth LLC bought a new stake in CalciMedica during the fourth quarter worth about $135,000. Finally, Renaissance Technologies LLC bought a new stake in shares of CalciMedica in the 4th quarter worth approximately $153,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.